A Cost Effectiveness Model of Long-Acting Reversible Contraceptive Methods in the Brazilian National Health System

Am J Prev Med. 2022 Jan;62(1):114-121. doi: 10.1016/j.amepre.2021.06.023.

Abstract

Introduction: The use of long-acting reversible contraceptives is low among adolescents owing to the high up-front cost. In this study, a 5-year cost-effectiveness model and budget impact analysis were used to compare the use of long-acting reversible contraceptives with the use of combined oral contraceptives among Brazilian adolescents.

Methods: A Markov model was developed to mirror the clinical and economic effects of long-acting reversible contraceptives among sexually active Brazilian adolescents in the public health system for a 5-year duration, starting from 2018. The costs were expressed in U.S.$, and a 5% discount rate was applied for both costs and benefits. Model inputs included costs of the contraceptive methods, contraceptive discontinuation and adherence rates, abortion, and birth costs associated with unintended pregnancies. The model outcomes were avoided pregnancies, abortions, and births. Univariate and probabilistic sensitivity analyses were conducted.

Results: Copper intrauterine device use was dominant 100% of the time for all outcomes, and a budget impact analysis revealed a cost savings of $422,431,269.10 in the 5-year period. Levonorgestrel intrauterine system and subdermal implant use were cost effective for all outcomes. The budget impact analyses revealed costs of $65,645,417.54 for levonorgestrel intrauterine system and $302,852,972.12 for subdermal implant use during the 5-year study period.

Conclusions: According to this Brazilian model, copper intrauterine device use is dominant, and levonorgestrel intrauterine systems and subdermal implants are more cost effective than combined oral contraceptives.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Contraception*
  • Contraceptive Agents
  • Contraceptive Devices
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Levonorgestrel*
  • Pregnancy

Substances

  • Contraceptive Agents
  • Levonorgestrel